Smith & Nephew SNATS Inc (SNN) — the peer cohort

As of 2026-09-18 — scores re-bake nightly. Cohort = shared Closelook index membership first, then sector. Diary readings, not advice.

Smith & Nephew SNATS Inc ranks 4 of 8 in its cohort on the Closelook composite (56/100) — the cohort is led by DexCom Inc at 66/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
SNN Smith & Nephew SNATS Inc 56 22 56 73 warn 25.4%
DXCM DexCom Inc 66 86 80 35 bull 5%
SECT-B.ST Sectra AB (publ) 58 67 65 11 bull 15.3%
SOON.SW Sonova H Ag 55 79 72 54 bull 5.2%
CEVI.ST CellaVision AB 54 64 69 31 bull 12.2%
SYK Stryker Corporation 52 21 66 43 bear 28.9%
MOVE.SW Medacta Group SA 47 10 57 32 warn 38%
ARGX argenx NV ADR 64 79 74 27 ok 7.7%

Scores are relative readings across the Closelook coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-09-18

Quick answers

Who are Smith & Nephew SNATS Inc's peers in the Closelook universe?

The cohort is drawn from shared Closelook index membership first, then sector: DexCom Inc (DXCM), Sectra AB (publ) (SECT-B.ST), Sonova H Ag (SOON.SW), CellaVision AB (CEVI.ST), Stryker Corporation (SYK), Medacta Group SA (MOVE.SW), argenx NV ADR (ARGX).

How does SNN score against its peers?

Smith & Nephew SNATS Inc's composite reads 56/100, ranking 4 of 8 in its cohort as of 2026-09-18; the cohort's highest composite is DexCom Inc at 66/100. Closelook scores are research diary readings, not ratings or advice.

Related in the Closelook universe

then Medical Devices. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.